Drawing for ADAPTABLE

USPTO serial 99545628

ADAPTABLE

Reviewed by CopyMark Law Group

Status 692
Filing date
Status date
Registration date
—
Examiner
MORENO, PAUL A
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ADAPTABLE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Makiko Coffland

Makiko Coffland Christensen O'Connor Johnson Kindness1201 Third Avenue, Suite 3600Seattle, WA 98101United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for use in the diagnosis, treatment, or prevention of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty related diseases or disorders, gynecological disorders, fertility, acromegaly and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases and disorders, muscle disorders, bone disorders, skeletal disorders, peripheral nervous system disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain; pharmaceutical preparations for aesthetic and therapeutic use, including for the diagnosis, treatment, or prevention of glabellar lines, forehead lines, lateral canthal lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations for skin careACTIVE—
009Downloadable computer software for scientific analysis within the medical field; computer hardware; downloadable data processing computer software; Computer hardware and recorded software systems for data processingACTIVE—
040Custom manufacture of pharmaceuticalsACTIVE—
042Scientific and technological services, namely, scientific research, analysis, testing, and diagnosis for the treatment or prevention of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty related diseases or disorders, gynecological disorders, fertility, acromegaly and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases and disorders, muscle disorders, bone disorders, skeletal disorders, peripheral nervous system disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain, glabellar lines, forehead lines, lateral canthal lines, facial wrinkles, asymmetries and defects and conditions of the human skin, skin care; scientific research and development; medical research; design and development of computer hardware and software; product design and development in the fields of pharmaceuticals, cosmetics, and medical devices; pharmaceutical products development; testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others; Medical research laboratory services; providing online, non-downloadable software for scientific analysis within the medical field; consultancy and information services relating to the scientific formulation of pharmaceutical products; pharmaceutical research servicesACTIVE—
044Pharmaceutical compounding services; dispensing of pharmaceuticals; medical services; healthcare services; providing medical information; consultancy and information services relating to pharmaceutical productsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 11, 2026ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 3, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 15, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 15, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 15, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 18, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 16, 2026DOCKASSIGNED TO EXAMINER—
Dec 12, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 12, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 12, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance